Back to top
more

Insulet (PODD)

(Real Time Quote from BATS)

$191.37 USD

191.37
508,447

-3.01 (-1.55%)

Updated Jul 25, 2024 03:53 PM ET

After-Market: $174.00 -17.37 (-9.08%) 4:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (98 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Nalak Das headshot

5 Stocks to Buy on the Dip to Gain From the Wall Street Rally

by Nalak Das

We have narrowed our search to five large-cap stocks with attractive valuations. These are TWLO, ZS, NEE, AWK and PODD.

Benjamin Rains headshot

3 Strong Stocks Down at Least 30% to Buy Now

by Benjamin Rains

Three S&P 500 stocks worth considering as buy-and-hold investments that are down at least 30% from their highs even as the market trades at records.

Here's Why You Should Buy Insulet (PODD) Stock Right Now

by Zacks Equity Research

Investors remain confident in the Insulet (PODD) stock due to the huge success of Omnipod 5.

Why Insulet (PODD) is a Top Growth Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Boston Scientific (BSX) Grows IC Business With New FDA Nod

by Zacks Equity Research

The AGENT DCB of Boston Scientific (BSX) is already available in Europe, parts of Asia Pacific and Latin America.

ICON (ICLR) Gains From Strategic Deals, New Innovations

by Zacks Equity Research

ICON (ICLR) continues to evolve its collaboration and delivery models, invest in technology, and enhance its project and program management capabilities.

Quest Diagnostics (DGX) Hurt by Lower Testing Sales, Competition

by Zacks Equity Research

Quest Diagnostics (DGX) faces intense competition, primarily from LabCorp as well as other commercial laboratories and hospitals.

Bruker (BRKR) Inks Definitive Agreement to Acquire ELITechGroup

by Zacks Equity Research

Bruker (BRKR) announces a share purchase agreement to acquire the molecular diagnostics innovator ELITechGroup.

Insulet (PODD) Q4 Earnings, Revenues Top Mark, Margins Expand

by Zacks Equity Research

In the fourth quarter, Insulet (PODD) achieves the milestone of 425,000 estimated active global customers using Omnipod products.

Alcon (ALC) Faces Rising Expenses, Tough Competitive Scenario

by Zacks Equity Research

In the surgical business, Alcon (ALC) faces a mix of competitors, ranging from large manufacturers with multiple business lines to small manufacturers.

Quanterix (QTRX) Expands in Alzheimer's Testing With Alliances

by Zacks Equity Research

Quanterix's (QTRX) blood-based biomarker testing offers a superior alternative, aligning with the recommendations of the NIA-AA criteria for AD diagnosis.

Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Down -15.31% in 4 Weeks, Here's Why You Should You Buy the Dip in Insulet (PODD)

by Zacks Equity Research

Insulet (PODD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Bruker's (BRKR) New Launches Drive Growth Amid FX Woes

by Zacks Equity Research

Bruker's (BRKR) revenues continue to be driven by the strength of end markets, including academic and government, and industrial.

Charles River (CRL) Forges Collaboration With Wheeler Bio

by Zacks Equity Research

Charles River (CRL) and Wheeler Bio join forces to accelerate the journey from discovery and CMC development to manufacturing.

Insulet (PODD) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates

by Zacks Equity Research

Although the revenue and EPS for Insulet (PODD) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Insulet (PODD) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Insulet (PODD) delivered earnings and revenue surprises of 108.96% and 10.79%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Countdown to Insulet (PODD) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS

by Zacks Equity Research

Beyond analysts' top -and-bottom-line estimates for Insulet (PODD), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2023.

Here's Why You Should Retain Insulet (PODD) Stock for Now

by Zacks Equity Research

The huge success of Omnipod 5 boosts investors' confidence in Insulet (PODD).

Insulet (PODD) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

Insulet (PODD) is expected to have benefited from the ongoing rollout of Omnipod 5 in several international markets in the fourth quarter.

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

IDEXX's (IDXX) Global Growth Continues, Currency Woes Persist

by Zacks Equity Research

A key element of IDEXX's (IDXX) customer engagement strategy is the expansion of its commercial footprint in a disciplined approach.

Insulet's (PODD) Omnipod 5 Gets CE Mark for Added Compatibility

by Zacks Equity Research

Insulet's (PODD) tubeless automated insulin delivery system's CE mark approval with multiple CGM sensor brands is likely to serve a wider patient pool.

Edwards Lifesciences (EW) Wins FDA Nod for the EVOQUE System

by Zacks Equity Research

Edwards Lifesciences' (EW) EVOQUE valve replacement system becomes the first transcatheter therapy to earn FDA approval for a tricuspid valve.

Reasons to Retain Quest Diagnostics (DGX) Stock for Now

by Zacks Equity Research

Strength of the base business bodes well for Quest Diagnostics (DGX).